PWP
TNYA icon

Parkwoods Wealth Partners’s Tenaya Therapeutics TNYA Stock Holding History

Parkwoods Wealth Partners’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7K Buy
18,500
+700
+4% +$532 ﹤0.01% 168
2026
Q1 		$12.3K Buy
17,800
+800
+5% +$590 ﹤0.01% 111
2025
Q4 		$12.1K Buy
17,000
+2,000
+13% +$2.72K ﹤0.01% 108
2025
Q3 		$24.3K Buy
+15,000
New +$15.1K 0.01% 96

Other funds holding TNYA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parkwoods Wealth Partners's TNYA Position: Q2 2026 in Review

Parkwoods Wealth Partners increased its Tenaya Therapeutics (TNYA) stake by 3.9% in Q2 2026, buying an estimated $532 and bringing the position to 18,500 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #168.

Parkwoods Wealth Partners first reported a position in TNYA in Q3 2025 and has held it in 4 quarters since. The position peaked at $24.3K in Q3 2025. 101 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • Parkwoods Wealth Partners held 18,500 shares of Tenaya Therapeutics worth $13.7K as of Q2 2026.
  • Parkwoods Wealth Partners bought 700 Tenaya Therapeutics shares in Q2 2026, an estimated $532.
  • Tenaya Therapeutics made up ﹤0.01% of Parkwoods Wealth Partners's portfolio in Q2 2026, its #168 holding.
  • Parkwoods Wealth Partners first reported a position in Tenaya Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Parkwoods Wealth Partners's Tenaya Therapeutics position peaked at $24.3K in Q3 2025.
  • 101 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on Parkwoods Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.